- Home
- NVNI vs QNTM Comparison
NVNI vs QNTM Comparison
Compare NVNI & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNI
- QNTM
- Stock Information
- Founded
- NVNI 2019
- QNTM 1998
- Country
- NVNI Brazil
- QNTM Canada
- Employees
- NVNI N/A
- QNTM N/A
- Industry
- NVNI
- QNTM
- Sector
- NVNI
- QNTM
- Exchange
- NVNI Nasdaq
- QNTM NYSE
- Market Cap
- NVNI 31.5M
- QNTM 35.6M
- IPO Year
- NVNI N/A
- QNTM N/A
- Fundamental
- Price
- NVNI $0.30
- QNTM $21.12
- Analyst Decision
- NVNI
- QNTM
- Analyst Count
- NVNI 0
- QNTM 0
- Target Price
- NVNI N/A
- QNTM N/A
- AVG Volume (30 Days)
- NVNI 1.9M
- QNTM 418.7K
- Earning Date
- NVNI 08-07-2025
- QNTM 08-13-2025
- Dividend Yield
- NVNI N/A
- QNTM N/A
- EPS Growth
- NVNI N/A
- QNTM N/A
- EPS
- NVNI N/A
- QNTM N/A
- Revenue
- NVNI $31,250,627.00
- QNTM N/A
- Revenue This Year
- NVNI $12.05
- QNTM N/A
- Revenue Next Year
- NVNI $15.02
- QNTM N/A
- P/E Ratio
- NVNI N/A
- QNTM N/A
- Revenue Growth
- NVNI 1491.58
- QNTM N/A
- 52 Week Low
- NVNI $0.14
- QNTM $2.70
- 52 Week High
- NVNI $12.19
- QNTM $38.25
- Technical
- Relative Strength Index (RSI)
- NVNI 40.66
- QNTM 53.38
- Support Level
- NVNI $0.28
- QNTM $20.89
- Resistance Level
- NVNI $0.33
- QNTM $38.25
- Average True Range (ATR)
- NVNI 0.03
- QNTM 4.31
- MACD
- NVNI -0.00
- QNTM 0.11
- Stochastic Oscillator
- NVNI 15.17
- QNTM 32.82
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.